Browse/search for people

Publication - Dr Lavinia Paternoster

    EMSY expression affects multiple components of the skin barrier with relevance to atopic dermatitis

    Citation

    Elias, MS, Wright, SC, Remenyi, J, Abbott, JC, Bray, SE, Cole, C, Edwards, S, Gierlinski, M, Glok, M, McGrath, JA, Nicholson, WV, Paternoster, L, Prescott, AR, Have, ST, Whitfield, PD, Lamond, AI & Brown, SJ, 2019, ‘EMSY expression affects multiple components of the skin barrier with relevance to atopic dermatitis’. Journal of Allergy and Clinical Immunology, vol 144., pp. 470-481

    Abstract

    BACKGROUND: Atopic dermatitis (AD) is a common, complex, and highly heritable inflammatory skin disease. Genome-wide association studies offer opportunities to identify molecular targets for drug development. A risk locus on chromosome 11q13.5 lies between 2 candidate genes, EMSY and LRRC32 (leucine-rich repeat-containing 32) but the functional mechanisms affecting risk of AD remain unclear.

    OBJECTIVES: We sought to apply a combination of genomic and molecular analytic techniques to investigate which genes are responsible for genetic risk at this locus and to define mechanisms contributing to atopic skin disease.

    METHODS: We used interrogation of available genomic and chromosome conformation data in keratinocytes, small interfering RNA (siRNA)-mediated knockdown in skin organotypic culture and functional assessment of barrier parameters, mass spectrometric global proteomic analysis and quantitative lipid analysis, electron microscopy of organotypic skin, and immunohistochemistry of human skin samples.

    RESULTS: Genomic data indicate active promoters in the genome-wide association study locus and upstream of EMSY; EMSY, LRRC32, and intergenic variants all appear to be within a single topologically associating domain. siRNA-knockdown of EMSY in organotypic culture leads to enhanced development of barrier function, reflecting increased expression of structural and functional proteins, including filaggrin and filaggrin-2, as well as long-chain ceramides. Conversely, overexpression of EMSY in keratinocytes leads to a reduction in markers of barrier formation. Skin biopsy samples from patients with AD show greater EMSY staining in the nucleus, which is consistent with an increased functional effect of this transcriptional control protein.

    CONCLUSION: Our findings demonstrate an important role for EMSY in transcriptional regulation and skin barrier formation, supporting EMSY inhibition as a therapeutic approach.

    Full details in the University publications repository